TE
Tema ETFs Portfolio holdings
AUM
$377M
This Quarter Return
-2.81%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$335M
AUM Growth
+$335M
(+39%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
31.69%
Top 10 Holdings %
Top 10 Hldgs %
28.51%
Holding
174
New
26
Increased
81
Reduced
34
Closed
27
Top Buys
| 1 |
Terex
TEX
|
$5.48M |
| 2 |
Herc Holdings
HRI
|
$4.98M |
| 3 |
Bristol-Myers Squibb
BMY
|
$4.58M |
| 4 |
Timken Company
TKR
|
$4.49M |
| 5 |
Eli Lilly
LLY
|
$4.13M |
Top Sells
| 1 |
Primoris Services
PRIM
|
$7.13M |
| 2 |
Fluor
FLR
|
$5.32M |
| 3 |
Federal Signal
FSS
|
$5.11M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.66M |
| 5 |
Ascendis Pharma
ASND
|
$2.02M |
Sector Composition
| 1 | Industrials | 43.38% |
| 2 | Healthcare | 33.02% |
| 3 | Utilities | 7.31% |
| 4 | Technology | 5.91% |
| 5 | Financials | 4.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Idexx Laboratories
IDXX
$51.8B
| $748K | 0.22% | 1,781 +1,045 | +142% | +$439K |
|
102
Day One Biopharmaceuticals
DAWN
$769M
| $723K | 0.22% | 91,123 +5,362 | +6% | +$42.5K |
|
103
Nurix Therapeutics
NRIX
$714M
| $703K | 0.21% | 59,146 +36,589 | +162% | +$435K |
|
104
CG Oncology
CGON
$2.04B
| $701K | 0.21% | 28,612 +20,283 | +244% | +$497K |
|
105
Insmed
INSM
$28.8B
| $700K | 0.21% | 9,181 -1,445 | -14% | -$110K |
|
106
Bio-Techne
TECH
$8.5B
| $660K | 0.2% | 11,252 +5,328 | +90% | +$312K |
|
107
Cboe Global Markets
CBOE
$24.7B
| $537K | 0.16% | +2,375 | New | +$537K |
|
108
Becton Dickinson
BDX
$55.3B
| $516K | 0.15% | 2,252 +1,330 | +144% | +$305K |
|
109
Mirum Pharmaceuticals
MIRM
$3.71B
| $515K | 0.15% | 11,432 -30,536 | -73% | -$1.38M |
|
110
West Pharmaceutical
WST
$17.8B
| $508K | 0.15% | 2,269 -911 | -29% | -$204K |
|
111
Fortinet
FTNT
$60.4B
| $503K | 0.15% | +5,222 | New | +$503K |
|
112
Align Technology
ALGN
$10.3B
| $486K | 0.15% | +3,059 | New | +$486K |
|
113
Akero Therapeutics
AKRO
$3.74B
| $477K | 0.14% | 11,778 -20,372 | -63% | -$825K |
|
114
Enliven Therapeutics
ELVN
$1.2B
| $465K | 0.14% | +23,648 | New | +$465K |
|
115
Viking Therapeutics
VKTX
$3.04B
| $464K | 0.14% | 19,231 -984 | -5% | -$23.8K |
|
116
Immunocore
IMCR
$1.62B
| $458K | 0.14% | 15,428 +4,234 | +38% | +$126K |
|
117
Teva Pharmaceuticals
TEVA
$21.1B
| $444K | 0.13% | 28,861 +3,199 | +12% | +$49.2K |
|
118
Guardant Health
GH
$8.41B
| $433K | 0.13% | 10,160 -25,960 | -72% | -$1.11M |
|
119
Neurocrine Biosciences
NBIX
$13.8B
| $432K | 0.13% | 3,904 +58 | +2% | +$6.42K |
|
120
Cogent Biosciences
COGT
$1.69B
| $429K | 0.13% | 71,563 +19,637 | +38% | +$118K |
|
121
Lantheus
LNTH
$3.73B
| $423K | 0.13% | 4,329 -3,633 | -46% | -$355K |
|
122
Zymeworks
ZYME
$1.12B
| $393K | 0.12% | +33,001 | New | +$393K |
|
123
Structure Therapeutics
GPCR
$1.11B
| $391K | 0.12% | 22,590 -21,753 | -49% | -$377K |
|
124
Arrowhead Research
ARWR
$3.05B
| $381K | 0.11% | 29,893 -31,610 | -51% | -$403K |
|
125
Replimune Group
REPL
$422M
| $366K | 0.11% | +37,522 | New | +$366K |
|